SUNNYVALE, Calif., Feb. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023.
BTIG-hosted events are intended for prospective and existing BTIG clients only. To request a one-on-one meeting with management or to listen to the live event, please contact your BTIG representative with interest.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Investor Contact
Aman Patel, CFA
ICR Westwicke
+1 (443) 450-4191
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.57 |
| Daily Change: | 0.02 1.29 |
| Daily Volume: | 774,173 |
| Market Cap: | US$157.880M |
May 05, 2025 April 30, 2025 February 05, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
